“Medicare will begin negotiating prices for top-selling drugs in 2023, but since the United States does not have a public health technology assessment entity that determines comparative effectiveness, the Centers for Medicare & Medicaid Services will need to conduct its own assessments for the drugs being negotiated," said Michael J. DiStefano, PhD.